PriceTargets.com logo

Alignment Healthcare - ALHC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.33
  • Forecasted Upside: -10.14%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$11.50 As of 10/30/2024 03:52 PM ET
▼ -0.21 (-1.79%)

This chart shows the closing price for ALHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alignment Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALHC

Analyst Price Target is $10.33
▼ -10.14% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Alignment Healthcare in the last 3 months. The average price target is $10.33, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a -10.14% upside from the last price of $11.50.

This chart shows the closing price for ALHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Alignment Healthcare. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/9/2023
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/7/2023
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2023
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/30/2024BarclaysBoost TargetUnderweight ➝ Underweight$7.00 ➝ $8.00
10/30/2024UBS GroupBoost TargetNeutral ➝ Neutral$9.00 ➝ $12.00
10/30/2024TD CowenBoost TargetBuy$10.00
10/11/2024KeyCorpInitiated CoverageSector Weight
8/14/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$10.00 ➝ $11.00
8/6/2024TD CowenBoost TargetBuy ➝ Buy$8.00 ➝ $10.00
8/6/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$8.00 ➝ $10.00
8/5/2024BarclaysBoost TargetUnderweight ➝ Underweight$4.50 ➝ $7.00
7/26/2024Stifel NicolausBoost TargetBuy ➝ Buy$9.00 ➝ $12.00
5/30/2024Baird R WUpgradeStrong-Buy
5/30/2024Robert W. BairdInitiated CoverageOutperform$10.00
5/30/2024Bank of AmericaUpgradeNeutral ➝ Buy$7.75 ➝ $11.00
5/8/2024Piper SandlerUpgradeNeutral ➝ Overweight$6.00 ➝ $8.00
5/3/2024StephensBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.00
4/23/2024Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $9.00
3/6/2024William BlairReiterated RatingOutperform
3/6/2024BarclaysInitiated CoverageUnderweight$4.50
3/6/2024Piper SandlerReiterated RatingOverweight ➝ Neutral$12.00 ➝ $6.00
2/28/2024UBS GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.50
1/24/2024Stifel NicolausInitiated CoverageBuy$11.00
1/9/2024StephensBoost TargetEqual Weight ➝ Equal Weight$10.00 ➝ $10.50
1/9/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$10.00 ➝ $12.00
12/21/2023UBS GroupBoost TargetNeutral ➝ Neutral$6.50 ➝ $9.00
11/2/2023Bank of AmericaDowngradeBuy ➝ Neutral$7.50 ➝ $7.25
10/16/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$9.00 ➝ $10.00
10/11/2023StephensInitiated CoverageEqual Weight$9.00
8/30/2023Morgan StanleyLower TargetOverweight ➝ Overweight$19.00 ➝ $12.00
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$19.00
7/7/2023JPMorgan Chase & Co.Lower Target$12.00 ➝ $10.00
5/5/2023UBS GroupLower Target$10.00 ➝ $8.00
5/5/2023SVB SecuritiesLower Target$24.00 ➝ $12.00
5/1/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$9.00
4/19/2023The Goldman Sachs GroupLower TargetBuy$14.00 ➝ $12.00
3/3/2023The Goldman Sachs GroupLower TargetBuy$21.00 ➝ $14.00
3/3/2023Piper SandlerLower TargetOverweight$19.00 ➝ $12.00
3/2/2023TD CowenLower TargetOutperform$17.00 ➝ $10.00
2/23/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$22.00 ➝ $12.00
11/21/2022Raymond JamesDowngradeOutperform ➝ Market Perform
9/8/2022Piper SandlerReiterated RatingOverweight$19.00
8/22/2022CowenBoost TargetOutperform$12.00 ➝ $17.00
8/22/2022CowenBoost Target$12.00 ➝ $17.00
8/10/2022Morgan StanleyBoost TargetOverweight$18.00 ➝ $19.00
8/8/2022The Goldman Sachs GroupBoost TargetBuy$14.00 ➝ $21.00
8/8/2022UBS GroupBoost TargetNeutral$11.00 ➝ $17.00
8/8/2022BarclaysBoost TargetOverweight$14.00 ➝ $21.00
8/5/2022Piper SandlerBoost TargetOverweight$15.00 ➝ $20.00
6/7/2022Morgan StanleyLower TargetOverweight$21.00 ➝ $18.00
5/26/2022Bank of AmericaUpgradeNeutral ➝ Buy$18.00 ➝ $14.00
5/5/2022William BlairReiterated RatingOutperform
4/4/2022Leerink PartnersInitiated CoverageOutperform$19.00
3/15/2022The Goldman Sachs GroupLower TargetBuy ➝ Buy$18.00 ➝ $16.00
3/7/2022The Goldman Sachs GroupLower TargetBuy$18.00 ➝ $16.00
3/7/2022Morgan StanleyLower TargetOverweight$25.00 ➝ $21.00
3/4/2022CowenLower TargetOutperform$24.00 ➝ $11.00
2/24/2022Piper SandlerLower TargetOverweight$25.00 ➝ $15.00
1/12/2022Raymond JamesLower TargetOutperform$30.00 ➝ $20.00
12/14/2021The Goldman Sachs GroupInitiated CoverageBuy$20.00
12/3/2021JPMorgan Chase & Co.Initiated CoverageOverweight$20.00
11/8/2021BarclaysBoost TargetOverweight$26.00 ➝ $28.00
9/9/2021CowenInitiated CoverageOutperform$24.00
8/31/2021Morgan StanleyLower TargetOverweight$38.00 ➝ $25.00
8/12/2021Raymond JamesLower TargetOutperform$36.00 ➝ $30.00
8/12/2021BarclaysInitiated CoverageOverweight$25.00
7/2/2021Morgan StanleyBoost TargetOverweight$36.00 ➝ $38.00
5/18/2021Raymond JamesBoost TargetOutperform$30.00 ➝ $36.00
4/20/2021Raymond JamesInitiated CoverageOutperform$30.00
4/20/2021Morgan StanleyInitiated CoverageOverweight$36.00
4/20/2021Bank of AmericaInitiated CoverageNeutral$29.00
4/20/2021William BlairInitiated CoverageOutperform
4/20/2021UBS GroupInitiated CoverageNeutral$28.00
4/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$25.00
4/20/2021Piper SandlerInitiated CoverageOverweight$30.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 13 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2024
  • 7 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 15 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 15 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 15 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Alignment Healthcare logo
Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Read More

Today's Range

Now: $11.50
Low: $11.06
High: $11.89

50 Day Range

MA: $10.62
Low: $8.84
High: $11.89

52 Week Range

Now: $11.50
Low: $4.46
High: $12.36

Volume

1,418,553 shs

Average Volume

1,016,079 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Alignment Healthcare?

The following Wall Street sell-side analysts have issued research reports on Alignment Healthcare in the last twelve months: Baird R W, Bank of America Co., Barclays PLC, KeyCorp, Piper Sandler, Raymond James, Robert W. Baird, Stephens, Stifel Nicolaus, TD Cowen, UBS Group AG, and William Blair.
View the latest analyst ratings for ALHC.

What is the current price target for Alignment Healthcare?

9 Wall Street analysts have set twelve-month price targets for Alignment Healthcare in the last year. Their average twelve-month price target is $10.33, suggesting a possible downside of 10.1%. UBS Group AG has the highest price target set, predicting ALHC will reach $12.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $7.00 for Alignment Healthcare in the next year.
View the latest price targets for ALHC.

What is the current consensus analyst rating for Alignment Healthcare?

Alignment Healthcare currently has 1 sell rating, 3 hold ratings, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALHC.

What other companies compete with Alignment Healthcare?

Other companies that are similar to Alignment Healthcare include Privia Health Group, Magellan Health, Phreesia, Healthcare Services Group and Cryoport. Learn More about companies similar to Alignment Healthcare.

How do I contact Alignment Healthcare's investor relations team?

Alignment Healthcare's physical mailing address is 1100 W. TOWN AND COUNTRY ROAD SUITE 1600, ORANGE CA, 92868. The company's listed phone number is 844-310-2247 and its investor relations email address is [email protected]. The official website for Alignment Healthcare is www.alignmenthealthcare.com. Learn More about contacing Alignment Healthcare investor relations.